Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study.

Trial Profile

Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Feb 2017

At a glance

  • Drugs Ethosuximide (Primary) ; Lamotrigine; Valproic acid
  • Indications Absence epilepsy
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 03 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 04 Mar 2010 Results have been published in the New England Journal of Medicine.
    • 15 Sep 2009 Planned end date changed from 1 Nov 2008 to 1 Nov 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top